This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

To help prevent pediatric IPD, protect against what matters, when it matters, with VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine)1,2

Deliver robust and early immunogenicity against critical serotypes during the first year of life and beyond.1

VAXNEUVANCE is administered as a 4-dose series at 2, 4, 6, and 12 through 15 months of age.

Choose VAXNEUVANCE for your pediatric patients

IPD protection against key disease-causing serotypes matters.1

Get details on serotypes

IPD protection during the first year of life matters, when the threat of IPD is highest.2-6

Learn about first year of life

VAXNEUVANCE delivers superior immune responses for critical IPD-causing Serotypes 3, 22F, and 33F and comparable immune responses for 12 shared serotypes.1,7,a-e

See immunogenicity data

VAXNEUVANCE is a CDC, AAP, and AAFP recommended conjugate vaccine option for your pediatric patients.6,8,9

View recommendations

VAXNEUVANCE was studied vs PCV13.

Randomized controlled trials assessing the clinical efficacy of VAXNEUVANCE compared to PCV13 have not been conducted.

No randomized controlled clinical trials have been conducted between PCV20 and VAXNEUVANCE in pediatric patients.10

default-sum-open-background-color
default-sum-close-background-color
false
default-sum-open-hover-color
default-sum-open-focus-color
default-sum-close-focus-color
.default-sum-close-hover-color

Study design

Study 8 was a pivotal, double-blind, active comparator-controlled study in which participants were randomized to receive VAXNEUVANCE (N=860) or PCV13 (N=860) in a 4-dose series. The first 3 doses were administered to infants at 2, 4, and 6 months of age and the fourth dose was administered to children at 12 through 15 months of age. Participants also received other licensed pediatric vaccines concomitantly. Immune responses were measured by IgG response rates, IgG GMCs, and OPA GMTs for all 15 serotypes contained in VAXNEUVANCE.

aMeasurements were taken 30 days postdose specified.
bSecondary endpoint: Postdose 3 IgG response rate percentage point difference vs PCV13 (95% CI): for Serotype 3, 19.1 (14.4, 24.0); for Serotype 22F, 8.1 (5.1, 11.5); for Serotype 33F, -5.1 (-9.5, -0.7).11
cSecondary endpoint: Postdose 4 IgG GMC ratio vs PCV13 (95% CI): for Serotype 3, 1.43 (1.30, 1.57); for Serotype 22F, 4.77 (4.28, 5.32); for Serotype 33F, 2.68 (2.40, 3.00).11
dSecondary endpoint: Postdose 3 lgG GMC ratio vs PCV13 (95% CI): for Serotype 3, 1.70 (1.54, 1.86).11
eThe 12 shared serotypes were ST1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.11

Don’t let your patients walk into toddlerhood without the robust and early protection of VAXNEUVANCE12

Image of VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) SyringeImage of VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) Syringe
Not shown at actual size
Not shown at actual size

Looking to stock VAXNEUVANCE in your practice?

Simply register or log into your account to get started.

Order VAXNEUVANCE

AAP, American Academy of Pediatrics; AAFP, American Academy of Family Physicians; CDC, Centers for Disease Control and Prevention; CI, confidence interval; GMC, geometric mean concentration (mcg/mL); GMT, geometric mean titer; IgG, Immunoglobulin G; IPD, invasive pneumococcal disease; OPA, opsonophagocytic activity; PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; ST, serotype.

View safety & tolerability data

View safety & tolerability data

Learn about special populations

Learn about special populations

See details on reimbursement

See details on reimbursement

Read frequently asked questions

Read frequently asked questions

References:

  1. Visualization – based on 2018-2022 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance (ABCs). Centers for Disease Control and Prevention. Updated July 22, 2024. Accessed August 27, 2024. https://data.cdc.gov/d/qvzb-qs6p/visualization
  2. Data available on request from the Merck National Service Center via email at daprequests@merck.com. Please specify information package US-PVC-02072.
  3. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed August 2021. Accessed May 9, 2024. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html
  4. Moraes-Pinto Ml, Suano-Souza F, Aranda CS. Immune system: development and acquisition of immunological competence. J Pediatr (Rio J). 2021;97(Sl):S59-S66.doi:10.1016/j.jped.2020.10.006.
  5. Wodi AP, Morelli V. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 1: Principles of vaccination. Centers for Disease Control and Prevention. Last reviewed August 2021. Accessed May 9, 2024.
  6. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States 2025. Updated November 21, 2024. Accessed December 2, 2024. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child­combined-schedule.pdf
  7. Prevnar 13. Prescribing Information. Pfizer; 2019.
  8. AAP. Vaccination recommendations by the AAP. Last updated September 16, 2024. Accessed October 29, 2024. https://www.aap.org/en/patient­care/immunizations/vaccination-recommendations-by-the-aap/?srsltid=AfmBOoofcAhavCOfwUxPrblSOhl3G57dh2NQE2polv6EFmt7VZFEjoM
  9. Immunization schedules. American Academy of Family Physicians. 2025. Accessed January 14, 2025. https://www.aafp.org/family-physician/patient­care/prevention-wellness/immunizations-vaccines/immunization-schedules.html
  10. Prevnar 20. Prescribing Information. Pfizer; 2023.
  11. Lupinacci R, Rupp R, Wittawatmongkol 0, et al. A phase 3, multicenter, randomized, double-blind, active-comparator controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen ofV114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023;41(5):1142-1152. doi:10.1016/j.vaccine.2022 .12.054
  12. Important milestones: your child by one year. Centers for Disease Control and Prevention. Last reviewed June 6, 2023. Accessed May 9, 2024. https://www.cdc.gov/ncbddd/actearly /milestones/milestones-lyr.html
ExternalSitePopup

By clicking on this link, you will be leaving Merck Vaccines.

Cancel
Proceed
Cancel
Proceed

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.